A Phase I/II Trial of AMG 102 and Erlotinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer.

Trial Profile

A Phase I/II Trial of AMG 102 and Erlotinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Rilotumumab (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 20 Jul 2016 Planned End Date changed from 1 Jan 2015 to 1 Dec 2016.
    • 08 Jul 2015 Status changed from recruiting to active, no longer recruiting as per results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top